[The effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI].
OBJECTIVE
To assess the safety and effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI.


METHODS
A total of 92 patients with ACS post successful PCI were randomly divided into atorvastatin 10 mg/d (group A) and atorvastatin 40 mg/d (group B) on top of the standard medical therapy. Blood were taken at baseline, 4, 12 and 24 weeks for serum alanine aminotransferase (ALT), lipids, high-sensitive C-reactive protein (hs-CRP) and matrix metalloprotease-9 (MMP-9) measurements. The major adverse cardiac events (MACE) were also observed.


RESULTS
There was no significant difference in medication withdrawn (2 vs. 3 cases) due to increased ALT (3 times higher than normal) and incidence of MACE (5 vs. 7 cases) between the groups. TC and LDL were significantly reduced in both groups 4 weeks and thereafter post medication compared to pre-treatment (P < 0.05) and the reduction was more significant in group B than that in group A at 24 weeks post medication (P < 0.05) while TG and HDL remained unchanged. hs-CRP was significantly reduced at 12 and 24 weeks in both groups compared to baseline and the reduction was more significant in group B than that in group A at 24 weeks. MMP-9 was significantly reduced in both groups 4 weeks and thereafter post medication compared to pre-treatment (P < 0.05) and the reduction was more significant in group B than that in group A at 12 weeks post medication (P < 0.05).


CONCLUSIONS
Both atorvastatin doses significantly reduced TC, LDL, hs-CRP and MMP-9 in ACS patients post PCI and the reduction was more significant in high dose atorvastatin group at 24 weeks while the MACE and drug withdraw rates were similar between the groups.
Dong
Shao-hong
SH
Department of Cardiology, The Second Clinical Hospital of Jinan University (Shenzhen People's Hospital), Shenzhen 518026, China. dsh266@medmail.com.cn
Wen
Jun-min
JM
Luo
Lin-jie
LJ
Chen
Ke-qi
KQ
Liang
Xin-jian
XJ
Li
Yi-fu
YF
Liu
Hua-dong
HD
Chen
Huan-zhan
HZ
Huang
Zhi-xin
ZX
Jiang
Xin
X
D054058:Acute Coronary Syndrome / Q000097:blood* / Q000188:drug therapy*; D000410:Alanine Transaminase / Q000097:blood; D015906:Angioplasty, Balloon, Coronary; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*
D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D002097:C-Reactive Protein; D000069059:Atorvastatin; D000410:Alanine Transaminase; D020780:Matrix Metalloproteinase 9